Immunotherapy

Papers
(The H4-Index of Immunotherapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Imaging of brain metastases treated with immune checkpoint inhibitors112
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study38
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma29
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma28
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia26
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study24
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy23
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study23
Disrupting neuro-immune feedback loops: novel targets to amplify cancer immunotherapy21
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15820
Postvaccination immune-mediated hepatitis: what do we really know?20
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers19
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?18
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data18
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis18
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas18
The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives18
0.21904706954956